A chronic lung infection with Pseudomonas aeruginosa is associated with an increased exacerbation and mortality rate in people affected by bronchiectasis. Inhaled antibiotics are frequently used in clinical practice to treat chronic infections with this bacterium. The PROMIS-I and PROMIS-II studies investigated the efficacy and safety of 12-month inhaled colistimethate sodium administration in patients with bronchiectasis and chronic P. aeruginosa infection.
Autoren
- Jens Dehn
Publikation
- InFo PNEUMOLOGIE & ALLERGOLOGIE
Related Topics
You May Also Like
- Case report: bronchobiliary fistula
Disguised as pneumonia
- Rehospitalization risk for cardiopulmonary diseases
Transition to the outpatient setting is crucial
- Telemonitoring
Home earlier: sensory T-shirt monitors vital functions
- Ginkgo biloba for mild dementia: new meta-analysis
Improvements in several domains relevant to everyday life
- From symptom to diagnosis
Dyspnea – Lung metastases
- Potential biomarkers for diagnostics, prognosis and therapy
Male infertility
- Artesunate in uro-oncology
Integrin modulation for the control of metastases in cisplatin-resistant bladder cancer
- Long-term study with dementia patients